Abstract:Background: Viral resistance to existing inhibitors and the time-dependent effectiveness of neuraminidase inhibitors have limited the number of antivirals that can be used for prophylaxis and therapeutic treatment of severe influenza infection. Thus, there is an urgent need to develop new drugs to prevent and treat influenza infection. Objective: The aim of this study was to design and synthesize a novel series of 2-ureidonicotinamide derivatives, and evaluate their anti-IAV activities. Furthermore, we predicted the abilities of these compounds inhibiting PA-PB1 subunit and forecasted the docking poses of these compounds with RNA polymerase protein (PDB ID 3CM8). Method: The novel designed compounds were synthesized using classical methods of organic chemistry and tested in vitro for their abilities inhibiting RNP and against influenza A virus. In addition, the 23 synthesized molecules were subjected to the generated pharmacophore Hypo1 to forecast the activity target PA-PB1 subunit of RNA polymerase. The ADMET pharmacokinetic parameters were calculated by the ADMET modules in Discovery Studio 2016. The docking results helped us to demonstrate the possible interactions between these compounds with 3CM8. Results: The synthesized 2-ureidonicotinamide derivatives were characterized as potent anti-influenza inhibitors. The target compounds 7b and 7c demonstrated significant antiviral activities, and could be considered as novel lead compounds of antiviral inhibitors. In addition, compound 7b revealed suitable ADME properties expressed, and might be a significant RNA polymerase inhibitor targeting PA-PB1 subunit based on the predictable results and the docking results. Conclusion: This study revealed a novel series of compounds that might be useful in the search for an effective drug against influenza virus.

Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1

Optimization and SAR research at the benzoxazole and tetrazole rings of JNJ4796 as new anti-influenza A virus agents, part 2

Discovery and SAR Study of Piperidine-Based Derivatives As Novel Influenza Virus Inhibitors.

Design, Synthesis and in Vitro Anti-Influenza A Virus Evaluation of Novel Quinazoline Derivatives Containing S-acetamide and NH-acetamide Moieties at C-4

Design, Synthesis, and Biological Evaluation of Novel Penindolone Derivatives As Potential Inhibitors of Hemagglutinin-Mediated Membrane Fusion.

Design,Synthesis and Anti-influenza Activities of Novel Neuraminidase Inhibitors

Studies on synthesis and structure-activity relationship (SAR) of derivatives of a new natural product from marine fungi as inhibitors of influenza virus neuraminidase.

Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors via Targeting 150-Cavity

Synthesis and Biological Evaluation of 2‐oxo‐pyrazine‐3‐carboxamide‐yl Nucleoside Analogues and Their Epimers As Inhibitors of Influenza A Viruses

Optimization of 4-Aminopiperidines As Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir

Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- a]pyrimidines as Inhibitors of Group 2 Influenza A Viruses

Design and synthesis of pinane oxime derivatives as novel anti-influenza agents

Synthesis and biological evaluation of baloxavir marboxil analogs for the treatment of influenza A (H<sub>1</sub>N<sub>1</sub>) virus

Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus

Identification of C5-NH2 Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability

Design, Synthesis and Biological Evaluation of "Multi-Site"-binding Influenza Virus Neuraminidase Inhibitors.

A Novel N-heterocycles Substituted Oseltamivir Derivatives As Potent Inhibitors of Influenza Virus Neuraminidase: Discovery, Synthesis and Biological Evaluation

Structure-based methoxyflavone derivatives with potent inhibitory activity against various influenza neuraminidases

Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity

Optimization of N-Substituted Oseltamivir Derivatives As Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.

Identification of the Imidazo[1,2- a]pyrazine Derivative A4 as a Potential Influenza Virus Nucleoprotein Inhibitor